STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Company

Acrivon Therapeutics, Inc.

Filed

April 15, 2024

Period of Report

April 11, 2024

Accession Number

0001062993-24-008378